

# Next Generation Sequencing - targeted panel

## Hereditary prostate cancer, version 1.2, 2-11-2021



### Technical information

DNA was enriched using Agilent SureSelect Custom Capture (ELID 3293151) and paired-end sequenced on the Illumina platform (outsourced). Data are demultiplexed with bcl2fastq2 Conversion Software from Illumina. Illumina DRAGEN Bio-IT Platform is used for read mapping to the genome and variant detection. The aim is to obtain a unique coverage of the coding regions (CDS) +/- 10 basepairs for the indicated transcripts of at least 20x. When unique coverage is between 10x and 20x, regions are manually checked in the BAM file. When below 10x, Sanger sequencing is deployed for those regions. The detected variants are filtered and annotated with Alissa Interpret software and classified with Alamut Visual. As no technique has a 100% sensitivity, we cannot exclude that pathogenic variants remain undetected. At this moment, there is not enough information about the sensitivity of this technique with respect to the detection of deletions and duplications of more than 15 nucleotides and of somatic mosaic variants (all types of sequence changes).



**Dept. Clinical Genetics**

HGNC approved gene symbol	OMIM gene ID (active link to omim.org)	Transcript	median depth	% covered >10x	% covered >20x
ATM	607585	NM_000051.3	1790	100,00	100,00
BRCA1	113705	NM_007294.3	2686	100,00	100,00
BRCA2	600185	NM_000059.3	2335	100,00	100,00
CHEK2	604373	NM_007194.4	1995	100,00	100,00
HOXB13	604607	NM_006361.5	2332	100,00	100,00
PALB2	610355	NM_024675.3	2587	100,00	100,00

- OMIM release used: 18-2-2021
- The statistics above are based on a set of 20 samples
- Median depth is the median of the mean sequence depth over the protein coding exons ( $\pm 10$ bp flanking introns)
- % Covered 10x and 20x describes the percentage of a gene's coding sequence ( $\pm 10$ bp flanking introns) that is covered at least 10x or 20x